Introduction
============

Urinary tract infection (UTI) is one of the most common childhood diseases, with a prevalence rate of 30% ([@B1], [@B2]). Data presented in 2007 showed that there were 10.5 million visits due to UTI (3), most of which occurred within one year after the first episode of UTI ([@B4]). This disease leads to serious complications such as renal scar, renal failure and hypertension ([@B5], [@B6]). Although UTI is a common condition among children, the nonspecific symptoms of UTI in this age group makes urine culture the sole reliable diagnostic test. However, the high chance of contamination of the sample and the relatively long waiting time for the results of the culture test, may postpone the diagnosis of UTI in children.

Some studies suggest that a combination of ultrasound, scintigraphy, and voiding cystography could improve the diagnosis of UTI ([@B7], [@B8]). However, even these imaging techniques do not have an acceptable diagnostic value in detecting UTI.

In the meantime, use of urinary biomarkers may be helpful in diagnosis of UTI. Neutrophil gelatinase-associated lipocalin (NGAL) has been introduced as a diagnostic biomarker for kidney disease in numerous studies. For example, in two previous meta-analyses, we found that serum/urinary concentration of NGAL has an acceptable value in diagnosis of acute kidney injury ([@B9], [@B10]). There are also other studies that have evaluated the value of NGAL in identifying UTI. For example, Valdimarsson et al. in 2017 showed that urinary NGAL has a sensitivity and specificity of 96 to 100% in diagnosis of UTI ([@B11]). Similar findings have been reported by Lee et al. ([@B12]). But Kitao et al. suggested that urinary NGAL level in patients with UTI has low precision in predicting patient outcomes ([@B13]). This disagreement led us to design the present systematic review and meta-analysis to determine the diagnostic value of NGAL in detection of UTI in children and adolescents.

Methods
=======

**- Study design**

The Meta-analysis of observational studies in epidemiology (MOOSE) guideline was used to summarize the evidence on value of NGAL in diagnosis of UTI in children and adolescents ([@B14]). We used a similar method with our previous published works to conduct the present meta-analysis ([@B15]-[@B20]).

**- Eligibility criteria**

In this systematic review and meta-analysis, all observational studies aimed at investigating the value of NGAL in detection of UTI in children and adolescents were included. Exclusion criteria were studies without a UTI group, duplicate articles, recurrent UTI, in vitro/animal studies, adult studies, and reviews.

PICO in the present study was defined as follows. Problem or study population (P): children with UTI; index test (I): urine and serum levels of NGAL; comparison (C): with non-UTI subjects; outcome (O): The desired outcome was the diagnostic value of NGAL in diagnosis of UTI.

-   **Search strategy**

The databases searched for in the present study included Medline through the PubMed, Embase, Scopus and ISI Web of Science. This study examined all indexed studies from the establishment of the database to the end of 2019. In addition, we performed manual searches on Google search engine, Google Scholar and bibliography of related articles. Keywords associated with UTI in combination with words related to NGAL were used to perform the search in the present meta-analysis. The search strategy at Embase database is reported in appendix 1.

-   **Data extraction**

The data were screened and summarized by two independent researchers. A checklist was used to summarize the data, including first author\'s name, year of publication, number of patients, age, sex, number of UTI and non-UTI patients, urinary and serum levels of NGAL, and follow-up duration. In addition, mean and standard deviation of NGAL level, NGAL cut-offs, true positive (TP), false positive (FP), true negative (TN), false negative (FN), sensitivity, specificity and area under the curve of NGAL were also recorded. The checklist was designed according to the PRISMA guidelines ([@B21]). It should be noted that after summarizing the data, the two researchers\' checklists were compared and any disagreement was resolved by consulting a third researcher.

**- Quality control of articles**

Risk of bias among included studies was assessed based on quality assessment of diagnostic accuracy studies (QUADAS-2) recommendations ([@B22]). Disagreement was resolved through discussion with a third researcher.

**- Statistical analysis**

Analyses were performed using STATA 14.0 statistical software, applying the "midas" or "metan" commands. Analyses were stratified based on urinary and serum level of NGAL.

At first, mean and standard deviation of urinary and serum levels of NGAL were compared between UTI and non-UTI groups. Finding was presented as standardized mean difference (SMD) with 95% confidence interval (95% CI). Publication bias was assessed using Egger\'s test and presenting funnel plot.

In the second part, we evaluated the discriminatory power of NGAL in identifying UTI in children and adolescents. For this purpose, the data were summarized as TP, FP, TN and FN. Findings were reported as area under the summary receiver operating characteristics (SROC) curve (AUC), sensitivity, specificity and diagnostic odds ratio with 95% CI. Publication bias was examined in this section using Deek\'s funnel asymmetry test. In all analyses, heterogeneity was assessed using I^2^ test.

Results
=======

**Study design**

Database search eventually identified 485 articles. After eliminating duplicates and performing initial screening, 54 articles were studied in full. Of these, 42 articles were excluded. Reasons for excluding the papers included non-UTI studies (n = 6), animal/in vitro studies (n = 5), lack of NGAL data (n = 2), duplicated reports (n = 2), absence of non-UTI group (n = 13), recurrent UTI (n = 1), adult studies (n = 4), and review articles (n = 7). Two conference papers that did not present our required data were excluded. Before excluding these two papers, we tried to obtain the required data using two strategies. First, we performed an extensive database search to find other published articles of the authors. Second, we sent two repetitive emails to corresponding authors. Finally, data from 12 studies were included in the present meta-analysis (11, 23-33) ([Figure 1](#F1){ref-type="fig"}). There were 5 prospective cross-sectional studies, 2 retrospective cross-sectional studies, and 5 case-control studies. The sample size of included studied varied from 62 patients to 444 patients (total sample size of 2112 children, 50.9% male). 724 children had UTI and 1388 were non-UTI. The most common method of measuring NGAL was ELISA. Nine studies assessed urinary NGAL, 1 study was performed on serum level of NGAL and 2 studies examined both serum and urine NGAL levels. [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} present the characteristics of included studies.

**Risk of bias and publication bias**

Quality control of the articles based on QUADAS-2 tools showed that the risk of bias in patient selection, flow and timing was high in 5 studies. This was due to the case-control nature of these studies. Sampling method was also retrospective in two studies. Therefore, the risk of bias in patient selection and flow and timing in these studies was unclear. In addition, the risk of bias and applicability of the index test was unclear in a study ([Table 3](#T3){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}). Finally, there was no evidence of publication bias in the present meta-analysis ([Figure 2](#F2){ref-type="fig"}).

**Meta-analysis**

**- The mean difference of urinary and serum NGAL levels between the UTI and non-UTI patients**

[Figure 3](#F3){ref-type="fig"} shows the mean difference of urinary and serum NGAL levels between UTI and non-UTI groups. As can be seen, both urinary levels (SMD = 1.11; 95% CI: 0.75 to 1.47; p \<0.001; I^2^ = 92.8; p \<0.001) and serum levels (SMD = 0.84; 95% CI: 0.08 to 1.60; p = 0.031; I^2^ = 89.8; p \<0.001) of NGAL were significantly higher in UTI group compared to non-UTI group. As can be seen, there is high heterogeneity between studies. A subgroup analysis was performed to find the source of heterogeneity. We could not find the source of heterogeneity. Study design (p = 0.781), setting of patients (p = 0.147), sample size (p = 0.457), prevalence of UTI (p = 0.481) and NGAL assay method (p = 0.538) did not affect the SMD of urinary NGAL.

-   **Diagnostic accuracy of urinary NGAL in detection of UTI**

Data from 11 studies were included in analyses of this section (11, 23-30, 32, 33). The AUC of urinary NGAL in diagnosis of UTI in children and adolescents was 0.90 (95% CI: 0.87 to 0.92) ([Figure 4](#F4){ref-type="fig"}). Sensitivity and specificity of urinary NGAL in detecting UTI were 0.85 (95% CI: 0.77 to 0.90) and 0.81 (95% CI: 0.70 to 0.89), respectively ([Figure 5](#F5){ref-type="fig"}). Additionally, diagnostic odds ratio of this urine biomarker was 23.78 (95% CI: 8.61 to 65.62).

Significant heterogeneity was also observed in this section (I^2^ between 93.16 to 100%). A subgroup analysis based on NGAL cut-off point was performed to find the source of heterogeneity. As [Table 4](#T4){ref-type="table"} shows, the cut-off points reported in the studies were divided into four groups of urinary NGAL level \<20 ng / ml, 20-29.9 ng / ml, 30-39.9 ng / ml and 40 ng / ml and over. We observed optimum performance of urinary NGAL in cut-off points of 30 to 39.9 ng / ml. Analyses showed that AUC of urinary NGAL in detection of UTI was 0.95 (95% CI: 0.93 to 0.97) when the cut-off point was in the range of 30-39.9 ng / ml. The sensitivity, specificity and diagnostic odds ratio of NGAL at these cut-off points were 0.89 (95% CI: 0.64 to 0.97), 0.89 (95% CI: 0.71 to 0.97) and 67 (95% CI: 5 to 891), respectively.

-   **Diagnostic accuracy of serum NGAL in detection of UTI**

Data from three studies were included in the analyses of this section ([@B26], [@B27], [@B31]). The AUC of serum NGAL in diagnosis of UTI in children and adolescents was 0.83 (95% CI: 0.80 to 0.86) ([Figure 4](#F4){ref-type="fig"}). Sensitivity and specificity of serum NGAL in detecting UTI were 0.85 (95% CI: 0.70 to 0.90) and 0.81 (95% CI: 0.69 to 0.88), respectively ([Figure 6](#F6){ref-type="fig"}). Diagnostic odds ratio of this serum biomarker was 9.53 (95% CI: 1.52 to 59.65). Despite the obvious heterogeneity, subgroup analysis was not performed because the number of articles was small.

Discussion
==========

The present meta-analysis showed that NGAL is able to detect UTI in children and adolescents. Stratified analysis showed that the urinary level of this biomarker had higher discriminatory power than its serum level and the optimum cut-off point was in the range of 30-39.9 ng / ml. When we assess the discriminatory precision of a test/biomarker, diagnostic odds ratio indicates the usefulness of the test/biomarker in the clinic. Urinary NGAL at cut-off points between 30-39.9 ng / ml had a diagnostic odds ratio of 67, which indicated its high applicability in diagnosis of UTI in children.

In the present study, significant heterogeneity was observed among the studies. Unfortunately, the origin of this heterogeneity was not determined by subgroup analysis. The only factor that partially reduced the heterogeneity was the difference in cut-off points. It should be noted that the concept of heterogeneity has changed in recent years. In general, tests used for heterogeneity are low powered so that they may not be able to detect heterogeneity when the number of articles is small. On the other hand, the test may falsely show a heterogeneity when the number of included articles was high. For this reason, researchers have recently suggested that numerical values of heterogeneity should be reported as descriptive statistics and it should be interpreted intuitively from the clinical perspective (34). The sensitivity and specificity reported in most studies included in the present meta-analysis were above 70%. Clinically, this level of sensitivity and specificity is divided into good and excellent groups, both of which represent good discriminatory performance of NGAL in diagnosis of UTI in children. Although the diversity of reported sensitivity and specificity between the studies was not clinically high, the I^2^ test indicated high heterogeneity between eligible studies. Therefore, it seems that the heterogeneity reported in I^2^ test has no clinically significant effect on the reported results.

The aim of the present study was to evaluate the value of NGAL in the first episode of UTI in children and adolescents. Therefore, the diagnostic value of NGAL in recurrent UTI was excluded. The reason for these exclusion criteria was reducing heterogeneity between studies. The pattern of urinary NGAL levels in recurrent UTI appears to be different from the first episode of UTI. For example, in 2017, Forster et al. showed that urinary NGAL level in recurrent UTI patients was significantly lower than first episode UTI patients. These researchers suggest that a defect in urinary NGAL production may be a prerequisite for recurrent UTI ([@B35]). Of course, this is still a hypothesis and further studies are needed to reach a definite conclusion.

Risk of bias regarding patient selection and flow and timing was high in 5 studies and unclear in 2 studies. This was due to the case-control design in 5 studies and retrospective sampling method in 2 other studies. However, since NGAL level was evaluated using a standard ELISA method, the applicability of the index test was rated as desirable in the present systematic review.

One of the issues that should be considered when examining diagnostic performance of a biomarker is its cost-effectiveness. Although NGAL may improve the management of children with UTI, its economic impact should also be considered. To the best of our knowledge, there is no study on the cost-effectiveness of NGAL in diagnosis of UTI in children. But Shaw et al. in 2011 showed that NGAL is a cost-effective biomarker for diagnosis of acute kidney injury ([@B36]). In another study involving 10,000 patients, Parikh et al. showed that use of urinary NGAL plus serum creatinine in diagnosis of acute kidney injury not only improves patient management but also reduces treatment costs ([@B37]).

###### 

Characteristics of included studies in assessment of mean difference of NGAL in detection of urinary tract infection

  **Author; year; country**    **Study type**   **Setting**          **Age**           **Sample size**   **No. of boys**   **number of patients UTI / Non UTI**   **UTI group**                 **Control group**   **NGAL assay methods**       **Source of NGAL**
  ---------------------------- ---------------- -------------------- ----------------- ----------------- ----------------- -------------------------------------- ----------------------------- ------------------- ---------------------------- --------------------
  Forster; 2018; USA           PCS              Neurogenic bladder   \<18              201               102               24 / 177                               UTI                           No UTI              ELISA                        Urine
  Jagadesan; 2019; India       PCS              Suspected UTI        0.2 to 5 years    100               43                34 / 66                                UTI                           No UTI              Turbidometric immunoassay    Urine
  Jung; 2018; Korea            RCS              Suspected UTI        \<3 month         422               267               102 / 320                              UTI                           No UTI              Microparticle immunoassays   Urine
  Kim; 2014; Korea             RCS              Suspected UTI        3.87±2.59 years   444               177               107 / 337                              UTI                           No UTI              ELISA                        Urine/Serum
  Krzemien; 2017; Poland       PCS              Suspected UTI        1 to 12 months    84                42                66 / 18                                Febrile and non-febrile UTI   No UTI              ELISA                        Urine/Serum
  Lubell; 2017; USA            PCS              Suspected UTI        0 to 2 years      260               118               35 / 225                               Febrile UTI                   Non-UTI             ELISA                        Urine
  Nickavar; 2016; Iran         CCS              UTI and non-UTI      0 to 12 years     63                23                37 / 26                                UTI                           Healthy control     ELISA                        Urine
  Safdar; 2015; Saudi Arabia   PCS              Suspected UTI        0 to 14 years     73                33                31 / 42                                UTI                           Non-UTI             NR                           Urine
  Seo; 2013; Korea             CCS              UTI and non-UTI      0-1 years         62                40                47 / 15                                UTI                           Healthy control     ELISA                        Serum
  Valdimarsson; 2017; Sweden   CCS              UTI and non-UTI      0-1 years         185               105               108 / 77                               UTI                           Healthy control     ELISA                        Urine
  Yilmaz; 2009; Turkey         CCS              UTI and non-UTI      0.1 to 14 years   89                24                60 / 29                                UTI                           Healthy control     ELISA                        Urine
  Yim; 2014; Korea             CCS              UTI and non-UTI      Mean 23 months    129               84                73 / 56                                UTI                           Healthy control     Immunosorbent assay          Urine

CCS: Case-Control study; ELISA: enzyme-linked immunosorbent assay; NGAL: neutrophil gelatinase-associated lipocalin; PCS: Prospective cross-sectional study; RCS: Cross-sectional study; UTI: Urinary tract infection.

###### 

Characteristics of included studies in assessment of diagnostic accuracy of NGAL in detection of urinary tract infection

  Author; year; country        **Sample size**   **No. of boys**   **number of patients UTI / Non UTI**   **UTI group**     **Control group**   **Source of NGAL**   **Cut-off ng/ml**   **TP**   **FP**   **FN**   **TN**
  ---------------------------- ----------------- ----------------- -------------------------------------- ----------------- ------------------- -------------------- ------------------- -------- -------- -------- --------
  Forster; 2018; USA           201               102               24 / 100                               UTI               No UTI              Urine                229                 20       14       4        86
  Jagadesan; 2019; India       100               43                34 / 66                                UTI               No UTI              Urine                27                  27       21       7        45
  Jung; 2018; Korea            422               267               102 / 320                              UTI               No UTI              Urine                46.2                92       24       10       296
  Kim; 2014; Korea             444               177               107 / 337                              UTI               No UTI              Urine                5.75                199      306      85       222
                                                                                                                                                Serum                65.35               134      151      57       81
  Krzemien; 2017; Poland       84                42                42 / 18                                Febrile UTI       No UTI              Urine                42.2                31       5        11       13
                                                                                                          Febrile UTI       No UTI              Serum                76.2                39       1        3        17
                                                                                                          Non-Febrile UTI   No UTI              Serum                39                  20       8        4        10
  Lubell; 2017; USA            260               118               35 / 225                               Febrile UTI       Non-UTI             Urine                39.1                34       10       1        215
  Nickavar; 2016; Iran         63                23                37 / 26                                UTI               Healthy control     Urine                0.2                 28       6        9        20
  Safdar; 2015; Saudi Arabia   73                33                31 / 42                                UTI               Non-UTI             Urine                35.83               25       10       17       21
  Seo; 2013; Korea             62                40                47 / 15                                UTI               Healthy control     Serum                61                  35       3        12       12
  Valdimarsson; 2017; Sweden   185               105               108 / 77                               UTI               Healthy control     Urine                38                  100      1        8        12
  Yilmaz; 2009; Turkey         89                24                60 / 29                                UTI               Healthy control     Urine                20                  58       7        2        22
  Yim; 2014; Korea             129               84                73 / 56                                UTI               Healthy control     Urine                23.95               60       9        13       47

FN: False Negative; FP: False positive; NGAL: neutrophil gelatinase-associated lipocalin; UTI: Urinary tract infection; TN: True negative; TP: True positive.

###### 

Risk of bias assessment among included studies

  --
  --

###### 

Diagnostic performance of NGAL in detection of UTI at different cut-offs

  Cut offs        **AUC**               **Sensitivity**       **Specificity**       **Positive LR**     **Negative LR**       **Odds ratio**
  --------------- --------------------- --------------------- --------------------- ------------------- --------------------- ----------------
  \<20 ng/ml      0.73 (0.69 to 0.77)   0.73 (0.63 to 0.80)   0.58 (0.32 to 0.80)   1.7 (0.9 to 3.4)    0.47 (0.25 to 0.89)   4 (1 to 14)
  20-29.9 ng/ml   0.85 (0.81 to 0.88)   0.88 (0.74 to 0.95)   0.76 (0.66 to 0.84)   3.7 (2.5 to 5.4)    0.16 (0.07 to 0.36)   23 (8 to 67)
  30-39.9 ng/ml   0.95 (0.93 to 0.97)   0.89 (0.64 to 0.97)   0.89 (0.71 to 0.97)   8.3 (2.4 to 28.7)   0.12 (0.03 to 0.53)   67 (5 to 891)
  \>40 ng/ml      0.92 (0.89 to 0.94)   0.84 (0.72 to 0.91)   0.87 (0.79 to 0.93)   6.4 (3.2 to 12.8)   0.19 (0.10 to 0.35)   34 (10 to 117)

AUC: area under the curve; LR: likelihood ratio.

![PRISMA flow diagram for the selection process](aaem-8-e56-g002){#F1}

![Risk of bias and publication bias among eligible studies. Risk of bias regarding patient selection and flow and timing was high in 5 studies and unclear in 2 studies. Risk of bias and applicability of index test was unclear in 1 study. There was no evidence of publication bias in standardized mean difference (p~Egger's\ test~=0.286) and discriminatory accuracy (p~Deek's\ test~=0.140) assessment of neutrophil gelatinase-associated lipocalin in detection of urinary tract infection](aaem-8-e56-g003){#F2}

![Standardized mean difference (SMD) of neutrophil gelatinase-associated lipocalin (NGAL) between urinary tract infected (UTI) and non-UTI children. Urine and serum levels of NGAL were significantly higher in UTI children. CI: Confidence interval](aaem-8-e56-g004){#F3}

![Area under the summary receiver operating characteristics (SROC) curve (AUC) of urine and serum neutrophil gelatinase-associated lipocalin (NGAL) in detection of urinary tract infection. CI: Confidence interval](aaem-8-e56-g005){#F4}

![Sensitivity, specificity, diagnostic score and diagnostic odds ratio of urine neutrophil gelatinase-associated lipocalin (NGAL) in detection of urinary tract infection. CI: Confidence interval](aaem-8-e56-g006){#F5}

![Sensitivity, specificity, diagnostic score and diagnostic odds ratio of serum neutrophil gelatinase-associated lipocalin (NGAL) in detection of urinary tract infection. CI: Confidence interval](aaem-8-e56-g007){#F6}

Conclusion
==========

The present meta-analysis showed that urinary NGAL had a high diagnostic value in detection of UTI in children and adolescents with an optimum cut-off point in the range of 30-39.9 ng/ml.
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